Article(id=1308467640859648175, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1308467640138227885, articleNumber=null, orderNo=null, doi=10.16438/j.0513-4870.2025-0741, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1751212800000, receivedDateStr=2025-06-30, revisedDate=1753372800000, revisedDateStr=2025-07-25, acceptedDate=null, acceptedDateStr=null, onlineDate=1789892595734, onlineDateStr=2026-09-20, pubDate=1760198400000, pubDateStr=2025-10-12, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1789892595734, onlineIssueDateStr=2026-09-20, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1789892595734, creator=13701087609, updateTime=1789892595734, updator=13701087609, issue=Issue{id=1308467640138227885, tenantId=1146029695717560320, journalId=1189982191388893191, year='2025', volume='60', issue='10', pageStart='2913', pageEnd='3262', issueExtLink='null', onlineDate='null', pubDate='1760198400000', pubDateStr='2025-10-12', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1789892595562, creator='13701087609', updateTime=1789893273356, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1308470483071033443, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1308467640138227885, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1308470483071033444, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1308467640138227885, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=2913, endPage=2917, ext={EN=ArticleExt(id=1308467641090334897, articleId=1308467640859648175, tenantId=1146029695717560320, journalId=1189982191388893191, language=EN, title=Enlightenment from Danggui Aloe Pills to the discovery of molecular glue, columnId=1190335349059588909, journalTitle=Acta Pharmaceutica Sinica, columnName=Professionals Forum, runingTitle=null, highlight=null, articleAbstract=

The target-based drug discovery (TBDD) alongside the resurgence of phenotypic drug discovery (PDD) constitute the dual-track paradigm for modern drug discovery. These two approaches are interactively applied and validated, accelerating the R&D of novel therapeutics. The microscopic structure of drugs (molecular structure and formulation properties) forms the basis for their macroscopic representations (pharmacological efficacy, physicochemical properties, adverse reactions, etc.), while these macroscopic properties represent the emergent characteristics arising from the interactions of microstructures. The applications of principles and techniques from molecular biology, biophysics, biochemistry, and analytical chemistry reveal the material essence and mechanisms of action at the micro-level, simultaneously mapping them onto various macro-level manifestations. Over three decades ago, the Chinese traditional medicines Danggui Lu Hui Wan (Angelica sinensis and Aloe Pill), investigated through phenotypic research, led to the development of meisoindigo for the treatment of chronic myeloid leukemia. Although its molecular target and mechanism of action were poorly understood at the time, it remains in clinical use today. Advances in science and technology have now enabled rigorous experimental design and execution, revealing meisoindigo's function as a molecular glue. It binds the target protein PKMYT1 while recruiting the E3 ligase TRIM25, forming a ternary complex that catalyzes the target protein's entry into the ubiquitin-proteasome system for degradation and functional loss. This micro-level elucidation explains its macro-level therapeutic efficacy. This article attempts to provide a concise commentary on this over-30-year R&D chain: "Danggui Lu Hui Wan → Indigo Naturalis → Indirubin → Meisoindigo → Molecular Glue, " aiming to bridge the gap between PDD and TBDD.

, authors=Zong-ru GUO*, authorsList=Zong-ru GUO, authorCompany=null, correspAuthors=Zong-ru GUO, authorNote=null, correspAuthorsNote=null, copyrightStatement=Copyright ©2025 Acta Pharmaceutica Sinica. All rights reserved., copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1308467643070046406, articleId=1308467640859648175, tenantId=1146029695717560320, journalId=1189982191388893191, language=CN, title=从当归芦荟丸到发现分子胶的启示, columnId=1190335349206389552, journalTitle=药学学报, columnName=专家论坛, runingTitle=null, highlight=null, articleAbstract=

以靶标为主导的药物发现和基于表型研制的复兴, 构成了当今新药创制的双轨模式, 两种范式交互应用与验证, 加速着新药的研发。药物的微观结构(分子结构和制剂性状) 是宏观表象(药理效应、物化性质和不良反应等) 的基础; 而宏观性质又是微观结构的相互作用所呈现的整体性质。当今应用分子生物学、生物物理、生物化学和分析化学原理和技术, 揭示了微观层面的物质本质和作用机制, 可同步映射出宏观层面的各种表现。30多年前由中药复方当归芦荟丸经表型研究, 创制出治疗慢性粒细胞白血病药物甲异靛, 虽然分子靶标和作用机制不甚明了, 但至今仍在应用。随着科学技术的进步, 通过一系列严谨的实验设计和实施, 揭示了甲异靛的分子胶功能, 揭示出甲异靛结合靶标蛋白PKMYT1, 又招募E3连接酶微观内涵, 诠释了宏观疗效。本文试图对此事隔30余年的“当归芦荟丸→青黛→靛玉红→甲异靛→分子胶”研发链作一简要述评, 拉近表型研究与靶标主导的研究模式。

, authors=郭宗儒*, authorsList=郭宗儒, authorCompany=null, correspAuthors=郭宗儒, authorNote=

作者贡献:

郭宗儒撰写全文, 对内容进行修改和补充。

, correspAuthorsNote=
郭宗儒, E-mail:
, copyrightStatement=版权所有©《药学学报》编辑部2025, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=qw2XA/J3yTUO45xuLB0BKw==, magXml=/FgkStpnOt/eG7WVFMkT0w==, pdfUrl=null, pdf=3vpHd/EDjKWHbRLxv0KWsA==, pdfFileSize=1297328, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=gqf9zkN95M7yYBAUqCOSkg==, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=Tp9FFBNONGDrWzbn6j/PWg==, mapNumber=null, fund=null)}, authors=[Author(id=1308497577616700053, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zrguo@imm.ac.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1308497579357336215, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, authorId=1308497577616700053, language=EN, stringName=Zong-ru GUO, firstName=Zong-ru, middleName=null, lastName=GUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1308497579457999512, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, authorId=1308497577616700053, language=CN, stringName=郭宗儒, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医学科学院、北京协和医学院药物研究所, 北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1308497577499259537, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, xref=null, ext=[AuthorCompanyExt(id=1308497577507648146, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, companyId=1308497577499259537, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1308497577516036755, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, companyId=1308497577499259537, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医学科学院、北京协和医学院药物研究所, 北京 100050)])])], keywords=[Keyword(id=1308497579848069785, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, orderNo=1, keyword=phenotypic research), Keyword(id=1308497579948733082, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, orderNo=2, keyword=mechanism of action), Keyword(id=1308497580053590683, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, orderNo=3, keyword=Danggui Lu Hui Wan), Keyword(id=1308497580124893852, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, orderNo=4, keyword=meisoindigo), Keyword(id=1308497580217168541, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, orderNo=5, keyword=molecular glue), Keyword(id=1308497580326220446, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, orderNo=1, keyword=表型研究), Keyword(id=1308497580435272351, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, orderNo=2, keyword=作用机制), Keyword(id=1308497580523352736, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, orderNo=3, keyword=当归芦荟丸), Keyword(id=1308497580674347681, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, orderNo=4, keyword=甲异靛), Keyword(id=1308497580754039458, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, orderNo=5, keyword=分子胶)], refs=[Reference(id=1308497583769744043, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=1, rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Vincent F, Nueda A, Lee J, et al. Phenotypic drug discovery: recent successes, lessons learned and new directions [J]. Nat Rev Drug Discov, 2022, 21: 899-914., articleTitle=null, refAbstract=null), Reference(id=1308497583866213036, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=2, rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Department of hematology, Hematology hospital, Chinese Academy of Medical Sciences; Department of Internal Medicine, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. Clinical study on Dangguiluhui pills in the treatment of chronic myeloid leukemia [J]. Chin J Intern Med (中华内科杂志), 1979, 18: 83-88., articleTitle=null, refAbstract=null), Reference(id=1308497584109482669, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=3, rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Department No. 6, Branch of Chinese Academy of Medical Sciences. Preliminary report on the experimental study of antileukemia effect of Danggui Aloe Pill [J]. Chin Tradit Herb Drugs (中草药), 1984, 15: 534-536., articleTitle=null, refAbstract=null), Reference(id=1308497584193368750, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=4, rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen DH, Xie JX. Chemical components of traditional Chinese medicine Indigo naturalis [J]. Chin Tradit Herb Drugs (中草药), 1984, 15: 6-8., articleTitle=null, refAbstract=null), Reference(id=1308497584302420655, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=5, rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Wu KM, Zhang MY, Fang Z, et al. Potential antileukemic agents, synthesis of derivatives of indirubin, indigo, and isoindigotin [J]. Acta Pharm Sin (药学学报), 1985, 20: 821-826., articleTitle=null, refAbstract=null), Reference(id=1308497584386306736, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=6, rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Ji XJ, Zhang FR. Studies on antineoplastic action of indirubin derivatives and analogues and their structure activity relationships [J]. Acta Pharm Sin (药学学报), 1985, 20: 137-139., articleTitle=null, refAbstract=null), Reference(id=1308497584465998513, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=7, rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Hoessel R, Leclerc S, Eedicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependant kinases [J]. Nat Cell Biol, 1999, 1: 60-67., articleTitle=null, refAbstract=null), Reference(id=1308497584549884594, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=8, rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang ZX, Li SY, Li FF, et al. Meisoindigo acts as a molecular glue to target PKMYT1 for degradation in chronic myeloid leukemiha therapy [J]. Adv Sci, 2025, 12: e2413676., articleTitle=null, refAbstract=null), Reference(id=1308497584629576371, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=9, rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Steinebach C, Bricelj A, Murgai A, et al. Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs [J]. J Med Chem, 2023, 66: 14513-14543., articleTitle=null, refAbstract=null), Reference(id=1308497584730239668, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=10, rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu TT, Yang H, Zhuo FF, et al. Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy [J]. eBioMedicine, 2022, 86: 104353., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1308497577499259537, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, xref=null, ext=[AuthorCompanyExt(id=1308497577507648146, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, companyId=1308497577499259537, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1308497577516036755, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, companyId=1308497577499259537, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医学科学院、北京协和医学院药物研究所, 北京 100050)])], figs=[ArticleFig(id=1308497581194441379, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, label=null, caption=null, figureFileSmall=ZVJ7fmEbNSo0Fvuh3KdfZw==, figureFileBig=AVz1VfXuu6rGrButmb7A+A==, tableContent=null), ArticleFig(id=1308497581345436324, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, label=Fig.1, caption=The binding mode of compound 5 to CDK2, figureFileSmall=ZVJ7fmEbNSo0Fvuh3KdfZw==, figureFileBig=AVz1VfXuu6rGrButmb7A+A==, tableContent=null), ArticleFig(id=1308497581517402789, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, label=null, caption=null, figureFileSmall=WcFVvxeLvtL0Y3DsTlHUVw==, figureFileBig=6GFnVrh2ZE2Uaq5o4zxePQ==, tableContent=null), ArticleFig(id=1308497581588705958, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, label=Fig.2, caption=Proposed mechanism of the interaction between meisoindigo and PKMYT1, figureFileSmall=WcFVvxeLvtL0Y3DsTlHUVw==, figureFileBig=6GFnVrh2ZE2Uaq5o4zxePQ==, tableContent=null), ArticleFig(id=1308497581660009127, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, label=null, caption=null, figureFileSmall=DAhXl1bkv05mYNxURH7gwg==, figureFileBig=rF5ZiLEyVWwendTBM6liaQ==, tableContent=null), ArticleFig(id=1308497581764866728, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, label=Fig.3, caption=The binding mode of meisoindigo to PKMYT1[8], figureFileSmall=DAhXl1bkv05mYNxURH7gwg==, figureFileBig=rF5ZiLEyVWwendTBM6liaQ==, tableContent=null), ArticleFig(id=1308497581848752809, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=EN, label=null, caption=null, figureFileSmall=MQlXw+RK+5Gn+uPAPOqIGQ==, figureFileBig=O9IW+z1/I50Ejx6FvU/heg==, tableContent=null), ArticleFig(id=1308497581987164842, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, language=CN, label=Fig.4, caption=Schematic diagram showing how meisoindigo acts as a molecular glue to enhance the interaction between PKMYT1 and TRIM25, triggering the degradation of PKMYT1 via the ubiquitin-proteasome pathway[8], figureFileSmall=MQlXw+RK+5Gn+uPAPOqIGQ==, figureFileBig=O9IW+z1/I50Ejx6FvU/heg==, tableContent=null)], attaches=null, journal=Journal(id=1189982048455397383, delFlag=0, nameCn=药学学报, nameEn=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, issn=0513-4870, eissn=null, cn=11-2163/R, coden=null, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=BTxjudbJDVO4PqdBR6On6Q==, journalPrice=null, startedYear=null, abbrevIsoEn=null, journalRemark=null, publicationField=null, createdTime=1761643429151, updatedTime=1788948913902, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Y, firstLetterEn=Y, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=BTxjudbJDVO4PqdBR6On6Q==, picEn=c4l1ckL55nWbhl1KrFdWIA==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509553505227679, language=CN, name=药学学报, nameHistory1=null, nameHistory2=null, managedBy=中国科学技术协会, sponsoredBy=中国药学会、中国医学科学院药物研究所, publishedBy=《药学学报》编辑委员会编辑出版, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948914171, updatedTime=1788948914171, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509553559753632, language=EN, name=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948914184, updatedTime=1788948914184, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1189982191388893191, websiteList=[Website(id=1189982271588340489, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/CN, language=CN, createTime=1761643482348, createBy=18614031015, updateTime=1761643498101, updateBy=18614031015, name=药学学报-中文, tplId=1146099689490845704, title=药学学报, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982873114448678, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=articleTextType, value=kx, createTime=1761643625763, updateTime=1761643625763, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873093477155, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=banner, value=null, createTime=1761643625758, updateTime=1761643625758, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873135420201, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=grayFlag, value=0, createTime=1761643625768, updateTime=1761643625768, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873085088546, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643625756, updateTime=1761643625756, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873152197419, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=minRunFlag, value=0, createTime=1761643625772, updateTime=1761643625772, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873110254373, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic, createTime=1761643625762, updateTime=1761643625762, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873143808810, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=silenceFlag, value=0, createTime=1761643625770, updateTime=1761643625770, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873101865764, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1761643625760, updateTime=1761643625760, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873122837287, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeColor, value=null, createTime=1761643625765, updateTime=1761643625765, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873127031592, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeStyle, value=null, createTime=1761643625766, updateTime=1761643625766, creator=18614031015, updator=18614031015)]), Website(id=1189982271655449355, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/EN, language=EN, createTime=1761643482364, createBy=18614031015, updateTime=1761643514085, updateBy=18614031015, name=药学学报-英文, tplId=1146101810881728533, title=Acta Pharmaceutica Sinica, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982903015633534, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=articleTextType, value=kx, createTime=1761643632892, updateTime=1761643632892, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902990467707, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=banner, value=null, createTime=1761643632886, updateTime=1761643632886, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903036605057, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=grayFlag, value=0, createTime=1761643632897, updateTime=1761643632897, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902982079098, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643632884, updateTime=1761643632884, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903053382275, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=minRunFlag, value=0, createTime=1761643632901, updateTime=1761643632901, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903007244925, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic, createTime=1761643632890, updateTime=1761643632890, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903044993666, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=silenceFlag, value=0, createTime=1761643632899, updateTime=1761643632899, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902998856316, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1761643632888, updateTime=1761643632888, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903019827839, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeColor, value=null, createTime=1761643632893, updateTime=1761643632893, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903028216448, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeStyle, value=null, createTime=1761643632895, updateTime=1761643632895, creator=18614031015, updator=18614031015)])], journalTitle=药学学报, weixinUrl=null, journalUrl=https://www.yxxb.com.cn/aps, iacademicId=null, status=1, seqNo=null, journalTitleEn=Acta Pharmaceutica Sinica, journalPhotoCn=BTxjudbJDVO4PqdBR6On6Q==, journalPhotoEn=c4l1ckL55nWbhl1KrFdWIA==, journalFirstLetter=Y, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/10.16438/j.0513-4870.2025-0741, detailUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-0741, pdfUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/PDF/10.16438/j.0513-4870.2025-0741, pdfUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/PDF/10.16438/j.0513-4870.2025-0741, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=1, orderTime=1760198400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
从当归芦荟丸到发现分子胶的启示
收藏切换
PDF下载
郭宗儒 *
药学学报 | 专家论坛 2025,60(10): 2913-2917
收起
收藏切换
药学学报 |专家论坛 2025 , 60 (10) : 2913 -2917
从当归芦荟丸到发现分子胶的启示
全屏
[Author(id=1308497577616700053, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=zrguo@imm.ac.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1308497579357336215, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, authorId=1308497577616700053, language=EN, stringName=Zong-ru GUO, firstName=Zong-ru, middleName=null, lastName=GUO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1308497579457999512, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, authorId=1308497577616700053, language=CN, stringName=郭宗儒, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医学科学院、北京协和医学院药物研究所, 北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1308497577499259537, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, xref=null, ext=[AuthorCompanyExt(id=1308497577507648146, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, companyId=1308497577499259537, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1308497577516036755, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1308467640859648175, companyId=1308497577499259537, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医学科学院、北京协和医学院药物研究所, 北京 100050)])])]
郭宗儒*
作者信息
  • 中国医学科学院、北京协和医学院药物研究所, 北京 100050
通讯作者:
郭宗儒, E-mail:
作者简介:

作者贡献:

郭宗儒撰写全文, 对内容进行修改和补充。

Enlightenment from Danggui Aloe Pills to the discovery of molecular glue
Zong-ru GUO*
Affiliations
  • Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
出版时间: 2025-10-12 doi: 10.16438/j.0513-4870.2025-0741
文章导航
收藏切换

以靶标为主导的药物发现和基于表型研制的复兴, 构成了当今新药创制的双轨模式, 两种范式交互应用与验证, 加速着新药的研发。药物的微观结构(分子结构和制剂性状) 是宏观表象(药理效应、物化性质和不良反应等) 的基础; 而宏观性质又是微观结构的相互作用所呈现的整体性质。当今应用分子生物学、生物物理、生物化学和分析化学原理和技术, 揭示了微观层面的物质本质和作用机制, 可同步映射出宏观层面的各种表现。30多年前由中药复方当归芦荟丸经表型研究, 创制出治疗慢性粒细胞白血病药物甲异靛, 虽然分子靶标和作用机制不甚明了, 但至今仍在应用。随着科学技术的进步, 通过一系列严谨的实验设计和实施, 揭示了甲异靛的分子胶功能, 揭示出甲异靛结合靶标蛋白PKMYT1, 又招募E3连接酶微观内涵, 诠释了宏观疗效。本文试图对此事隔30余年的“当归芦荟丸→青黛→靛玉红→甲异靛→分子胶”研发链作一简要述评, 拉近表型研究与靶标主导的研究模式。

表型研究  /  作用机制  /  当归芦荟丸  /  甲异靛  /  分子胶

The target-based drug discovery (TBDD) alongside the resurgence of phenotypic drug discovery (PDD) constitute the dual-track paradigm for modern drug discovery. These two approaches are interactively applied and validated, accelerating the R&D of novel therapeutics. The microscopic structure of drugs (molecular structure and formulation properties) forms the basis for their macroscopic representations (pharmacological efficacy, physicochemical properties, adverse reactions, etc.), while these macroscopic properties represent the emergent characteristics arising from the interactions of microstructures. The applications of principles and techniques from molecular biology, biophysics, biochemistry, and analytical chemistry reveal the material essence and mechanisms of action at the micro-level, simultaneously mapping them onto various macro-level manifestations. Over three decades ago, the Chinese traditional medicines Danggui Lu Hui Wan (Angelica sinensis and Aloe Pill), investigated through phenotypic research, led to the development of meisoindigo for the treatment of chronic myeloid leukemia. Although its molecular target and mechanism of action were poorly understood at the time, it remains in clinical use today. Advances in science and technology have now enabled rigorous experimental design and execution, revealing meisoindigo's function as a molecular glue. It binds the target protein PKMYT1 while recruiting the E3 ligase TRIM25, forming a ternary complex that catalyzes the target protein's entry into the ubiquitin-proteasome system for degradation and functional loss. This micro-level elucidation explains its macro-level therapeutic efficacy. This article attempts to provide a concise commentary on this over-30-year R&D chain: "Danggui Lu Hui Wan → Indigo Naturalis → Indirubin → Meisoindigo → Molecular Glue, " aiming to bridge the gap between PDD and TBDD.

phenotypic research  /  mechanism of action  /  Danggui Lu Hui Wan  /  meisoindigo  /  molecular glue
郭宗儒. 从当归芦荟丸到发现分子胶的启示. 药学学报, 2025 , 60 (10) : 2913 -2917 . DOI: 10.16438/j.0513-4870.2025-0741
Zong-ru GUO. Enlightenment from Danggui Aloe Pills to the discovery of molecular glue[J]. Acta Pharmaceutica Sinica, 2025 , 60 (10) : 2913 -2917 . DOI: 10.16438/j.0513-4870.2025-0741
以宏观表象与微观结构的视角考察药物和药物作用, 是从不同的层面分析其内涵, 分别是药物及其作用的整体与部分、现象与本质、可观测行为与内在机制之间的复杂联系。微观结构是宏观表象的基础与根据(组成、相互作用和涌现性等); 宏观表象是微观结构的体现与约束(可观测性、边界、功能和目的等)。药物的分子结构诸如原子种类、键合方式和空间构型(微观) 决定其物理化学性质、药理活性和不良反应(宏观)。药物和靶标的互作本质是原子间的弱结合或共价键结合(微观), 表现为能量变化、构象变化、物质转化和功能改变等。药物发现过程饱含着宏观和微观层面的转换和互作。
早期基于表型的药物发现(phenotypic drug discovery, PDD) 是以细胞、组织、器官或动物整体为模型评价和发现药物的, 经典的实例是柳条水-水杨酸-阿司匹林的故事, PDD与天然物在当时是发现新药的佳配。分子生物学的发展使得基于靶标的药物发现(target-based drug discovery, TBDD) 占据主导地位, 众多靶向药物的涌现是TBDD的繁荣标志。近年来PDD的复兴(犹如共价键药物复兴) 成为研制复杂难治疾病药物的新策略, 因为可在新的技术层面上扩大可药性靶标的范围, 体现多向药理学特征, 也有助于使药物分子小型化[1]。本文不拟讨论当今PDD的进展和细节, 而是以抗白血病药物甲异靛的今昔, 讨论PDD和TBDD关系, 着重于后者理念上的展示。
当归芦荟丸是中药古方, 由大黄、黄柏、黄芩、黄连、栀子、龙胆草、芦荟、青黛、当归和木香等10味中药炮制而成, 具有清肝火、除烦热的功效。近代临床发现当归芦荟丸具有消炎杀菌和抗肿瘤的功效。中国医学科学院血液学研究所用作治疗慢性粒细胞白血病, 显示一定疗效[2, 3], 遂进行了深入研究。
研究者为了简化组方和找出有效部位或成分, 考虑到方剂中的芦荟和青黛有抗菌消炎作用, 设计如下分组实验: 十味全方、芦荟加青黛二味药、单味芦荟和单味青黛等4组, 经灌胃小鼠白血病L-7212模型, 每日一剂, 连续10日, 评价对小鼠肿瘤生长的影响。结果表明, 芦荟加青黛有一定疗效, 生存时间延长17%, 单用青黛的生存时间延长16.3%, 而单用芦荟组无效。说明芦荟加青黛组的效果来自青黛。青黛对白血病L-7212有抑制作用, 对其他肿瘤生长没有活性。
青黛是由大青叶(Folium isatidis, FI) 和板蓝根(Radix isatidis, RI) 与石灰混合发酵而制得。为了确定有效成分, 研究了其原料大青叶、板蓝根以及青黛, 用不同方法萃取, 灌胃L-7212小鼠, 结果只有酸性热水萃取物冷后析出的深色固体呈现活性, 而大青叶或板蓝根或青黛的水或醇萃取物未显示活性。提示活性成分应是难溶于水和乙醇、可溶于酸性水液的有机物。深色固体物质意味着化学结构中有共轭系统和生色团, 后经结构分析证明是靛玉红。
陈棣华和谢晶曦[4]从蓼科植物蓼蓝(Polygonum tinctorium) 炮制加工的青黛分离得到靛玉红(1, indirubin)、靛蓝(2, indigotin)、N-苯基-2-萘胺、β-谷甾醇(β-sitesterol) 和虫漆蜡醇(laccerol) 等多种单体天然化合物。
靛玉红是由两个吲哚啉酮经2, 3′双键偶联成的二聚物, 分子呈平面的共轭系统, 为暗红色针状结晶。经药理实验研究, 表明对多种移植性动物肿瘤有抑制作用, 破坏白血病细胞。还认为作用靶标为DNA聚合酶, 抑制DNA聚合, 而对蛋白质的合成没有直接影响, 此外, 靛玉红还可增强动物单核巨噬细胞的吞噬能力。靛玉红可口服吸收, 后经临床研究, 表明靛玉红可治疗慢性粒细胞白血病。
靛玉红分子量262.26, 但水中几乎不溶, 原因是在共轭平面结构的分子间形成氢键, 导致高晶格能, 水分子的热运动难以克服晶格能, 这可由靛玉红的熔点高达365 ℃得到佐证。靛玉红的N1上氢原子可与C2′的羰基氧形成分子内氢键, N1不是高晶格能的起因, 而是N1′的氢原子与另一靛玉红形成分子间氢键。因而在N1′上作不同烷基取代, 可阻止分子间缔合。
为此合成了N1′一系列烷基取代物, 同时对靛蓝和异靛蓝的结构修饰也以C1~C3烷基取代, 结果呈现类似于靛玉红的活性趋势, 其中N-甲基异靛蓝(3) 活性显著强于其他化合物, 进而将3种母核的高活性化合物作活性比较, 3的活性优胜于其他化合物[5, 6]。
化合物3被确定为候选物, 定名甲异靛(meisoindigo), 经系统的临床前研究和Ⅲ期临床试验, 表明甲异靛是口服治疗慢性粒细胞白血病的有效药物, 于1992年经我国药监部门批准上市, 应用至今。
基于表型变化而研制成功的甲异靛上市30多年来一直在临床应用, 但对其作用靶标和分子机制仍未解析。最近却有了突破, 是由于分子生物学、各种组学和化学信息学方法协同研究的结果。
Hoessel等[7]研究靛玉红的作用靶标, 制备了3-肟基靛玉红(4), 抑制CDK周期蛋白依赖性激酶2 (CDK2) 活性IC50 0.18 µmol·L-1。为了提高靛玉红溶解度制备了靛玉红-5′-磺酸(5), 与CDK2复合物制备单晶, X-射线衍射分析提示, 分子定位于CDK2激酶的ATP结合域, 主要是通过范德华作用和3个氢键结合, 后者包括N1′-H与Glu81的C=O、C2′=O与Phe82骨架的NH, N1-H与Leu83的C=O形成氢键, 如图1所示。这个报道是与甲异靛结构最类似的化合物晶体结合模式。
基于活性蛋白质组学分析(activity-based protein profiling, ABPP), Zhang等[8]为寻找甲异靛的结合靶标首先制备了甲异靛的类似物6, 用N-己炔基置换N-甲基, 炔基作为点击反应的位点, 与另一含叠氮基(azido) 化合物形成连三唑杂环而偶联。6与K562细胞温孵表明活性与甲异靛有相同的作用机制。
进而, 6与K562活细胞温孵, 溶解细胞, 加入荧光物质四甲基罗丹明(TMRA) 的叠氮化合物(TMRA-azide), 使与6的炔基发生点击反应, 经SDS-PAGE凝胶电泳和凝胶荧光扫描, 表明随着6的浓度提高被标记的蛋白增加。然后以同样的条件和过程, 将发生点击反应的标识物换作生物素叠氮化物(biotin-azide), 富集被标记的蛋白, 消化成多肽, 用串联质谱标签(MT) 法作定量蛋白质组分析。对6捕获的蛋白与对照组作比较, 发现只有7个不同的蛋白, 而且分子量都低于100 kDa, 研究发现细胞中只有PKMYT1和ERG1蛋白的分子量在55~70 kDa。
为了确定甲异靛的作用靶标, 进行了原位沉降测定, 证明甲异靛对PKMYT1蛋白有非常强的竞争性结合作用。在2倍于6的浓度下可以完全置换出6的结合, 而对其他蛋白没有这样强的结合力。进而证明了与重组的PKMYT1和全长的PKMYT1结合作用都是浓度依赖性的结合。用K562细胞测定甲异靛的细胞热迁移实验, 表明与胞内PKMYT1的结合增高了对热的稳定性。
为了证明甲异靛的抗癌作用就是源于对PKMYT1的抑制, 采用CRISPR-Cas9基因编辑敲除K562细胞内PKMYT1基因, 结果表明细胞的生长和增殖受到显著抑制。还发现敲除PKMYT1的K562细胞, 减弱了原来受甲异靛抑制的细胞增殖作用。体内易位异种移植实验也证明接种敲除了PKMYT1的K562细胞的小鼠肿瘤生长(重量和体积) 与接种野生型细胞作比较, 都受到显著抑制。
甲异靛结构中含有α, β-不饱和酮片段, 为迈克尔亲电性基团, 6与含有巯基的谷胱甘肽(GSH) 预温孵, 则失去了与PKMYT1的结合能力。LC-MS证明甲异靛也与GSH发生共价结合, 当甲异靛经还原反应失去亲电加成能力就不能发生结合, 也失去了抗癌活性。
重组的PKMYT1蛋白与甲异靛温孵, 经消化成多肽后作LC-MS/MS分析, 表明是与Cys-301共价结合。PKMYT1蛋白结构中含有6个Cys, 为确定是哪个半胱氨酸残基, 用Ala逐个替换Cys的蛋白(丙氨酸扫描) 与甲异靛温孵证明结合于Cys-301。还证明了甲异靛与半胱氨酸结合是可逆性反应。反应过程中, 由于加成反应失去了共轭系统, 紫红色的溶液逐渐变淡。然后用乙酸乙酯萃取时, 溶液又变成深色, 提示逆反应又恢复了甲异靛的共轭结构。甲异靛与PKMYT1结合使蛋白变性, 却可回收近70%的甲异靛原型药, 说明蛋白失活不是化学计量的消耗甲异靛, 推断不是甲异靛的1∶1的直接作用。图2是甲异靛与PKMYT1-Cys-301可逆性共价结合的示意图。
动力学分子模拟甲异靛与PKMYT1蛋白的结合(200 ns), 最终稳定的构象是以直立键与Cys301结合, 两个吲哚酮还突出在蛋白表面外, 如图3所示, 这个独特的取向似乎预示着还能与其他蛋白发生相互作用(分子胶的联想), 助长并稳定这种取向的一个重要因素是甲异靛的酰氨与Asn302之间发生氢键结合。
PKMYT1是丝氨酸/苏氨酸激酶Wee家族一员, 催化周期蛋白依赖的激酶1 (CDK1) 的残基Thr14磷酸化, 从而抑制其启动有丝分裂功能。鉴于甲异靛直接与PKMYT1结合, 但并不抑制其活性, 这与甲异靛没有结合于活性中心相一致。
然而K562细胞与增高浓度的甲异靛温孵, PKMYT1蛋白表达量显著减少, 也伴随着降低了CDK1-Thr14磷酸化。实验还表明甲异靛不影响PKMYT1的mRNA的表达, 提示是在翻译后下调了PKMYT1。这些预示了甲异靛是促进PKMYT1降解的小分子。
细胞内蛋白质降解主要有两种途径: 泛素-蛋白酶体系统(UPS) 和自噬-溶酶体途径(ALP)。为了揭示甲异靛降解PKMYT1机制, 在与K562细胞温孵液中加入蛋白酶体抑制剂MG132, 结果可显著阻断甲异靛对PKMYT1降解量; 另一实验是加入溶酶体抑制剂巴佛洛霉素(bafilomycin), 结果对PKMYT1表达量没有影响, 从而证明甲异靛是通过UPS起作用的。进而用免疫共沉淀(Co-IP) 方法检测PKMYT1蛋白质泛素化修饰, 证实甲异靛促进了PKMYT1的泛素化。
为了确定参与PKMYT1降解的E3连接酶, 通过交叉分析PKMYT1与E3连接酶文库的相互作用, 初筛发现TRIM25、MARCHF5、RNF4和SKP2等4个蛋白可能是E3连接酶。用免疫共沉淀实验发现在HEK293T细胞中过表达的Flag-PKMYT1蛋白在甲异靛存在下增强了与TRIM25酶的结合, 微量热泳动实验(MST, 一种定量评价蛋白-蛋白互作的方法) 表明重组的PKMYT1与TRIM25的结合常数Kd = 2.94 μmol·L-1。
体外方法确定目标靶标PKMYT1和E3连接酶TRIM25的动态结合作用, 经MST实验表明甲异靛与PKMYT1结合作用Kd = 0.22 μmol·L-1。当甲异靛与PKMYT1预温孵后, 后者与TRIM25的结合剧增Kd = 86.8 nmol·L-1, 提高了33倍, 提示甲异靛作为分子胶提升了E3对目标蛋白的亲和力, 促进了泛素化。用基于多相分离的蛋白相互作用报告(SPPIER) 实验确证了在活细胞中生成了PKMYT1-甲异靛-TRIM25三元复合物[8]。从而证明了甲异靛作为分子胶, 是结合PKMYT1配体, 也是E3连接酶TRIM25的招募剂, 揭示了甲异靛抗白血病的分子机制是以分子胶催化了目标蛋白的泛素化, 引起蛋白酶体的降解。图4是PKMYT1-甲异靛-TRIM25互作并促进蛋白酶体对靶标蛋白PKMYT1降解的示意图。
33年前中国医学科学院药物研究所的老一辈科学家通过表型实验方法发现了靛玉红, 发明了甲异靛, 而今同所的新一代学者[8]阐明了甲异靛的作用靶标和分子胶的降解机制, 1/3世纪的跨域彰显了从宏观到微观研究的接续和科技之进步, 基因编辑和敲除、化学蛋白质组学、细胞内的有机点击反应和富集, 微量热涌动实验、串联质谱阐明蛋白质和多肽的标记与定位, 分子动力学模拟, 药物-靶标复合物的三维结构确证等, 这些微观层面的研究, 揭示了宏观表象的本质。甲异靛的分子胶功能为设计药物分子提供了新的素材和组件, 犹如自沙利度胺作为CRBN招募剂研制PROTAC以来, 已优化出剖裂邻苯二甲酰亚胺环, 得到更有效率的新型招募剂。数个Ⅲ期临床试验的候选物, 结构中含有苯(甲酰) 氨基戊二酰亚胺片段[9]。甲异靛作为不同于度胺类新型结构的E3招募剂, 结构优化有很大的空间, 例如双吲哚啉酮经3, 3′双键连接, 大π键弥散于整个分子, 纵然有一甲基阻挠分子间氢键, 但过于刚性和π-π堆集, 使得水和乙醇中溶解度极小, 降低共轭体系适度增加柔性键, 有望得到高活性的TRIM25招募剂。如今, 与30多年前不同的是, 宏观实验和微观解析得以同步进行, 相得益彰。如同发现蟾酥的有效成分蟾酥灵(bufalin) 具有抗癌作用同时, 屠鹏飞和曾克武等也证明是分子胶的作用机制[10], 演绎出宏观表象与微观结构解析的同步互作型研究。
从当归芦荟丸通往新型分子胶的桥梁是科学家的智慧和科技之进步。正是:
岐黄古卷蕴玄英, 当归芦荟济苍生。
十味拆方析效果, 百回炼就靛玉红。
慧眼识珠改构物, 甲基破解晶格能。
甲异靛降慢粒白, 赢得新药倚表型。
三十年后探幽径, 靶向昭昭历历情。
巧引酶连呈互作, 蛋白酶体若神灵。
分子胶合揭奥义, 只缘共轭烯二酮。
谁言草木无奇志? 表象微观万籁鸣!

参考文献 引证文献
排序方式:
1
Vincent F, Nueda A, Lee J, et al. Phenotypic drug discovery: recent successes, lessons learned and new directions [J]. Nat Rev Drug Discov, 2022, 21: 899-914.
2
Department of hematology, Hematology hospital, Chinese Academy of Medical Sciences; Department of Internal Medicine, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. Clinical study on Dangguiluhui pills in the treatment of chronic myeloid leukemia [J]. Chin J Intern Med (中华内科杂志), 1979, 18: 83-88.
3
Department No. 6, Branch of Chinese Academy of Medical Sciences. Preliminary report on the experimental study of antileukemia effect of Danggui Aloe Pill [J]. Chin Tradit Herb Drugs (中草药), 1984, 15: 534-536.
4
Chen DH, Xie JX. Chemical components of traditional Chinese medicine Indigo naturalis [J]. Chin Tradit Herb Drugs (中草药), 1984, 15: 6-8.
5
Wu KM, Zhang MY, Fang Z, et al. Potential antileukemic agents, synthesis of derivatives of indirubin, indigo, and isoindigotin [J]. Acta Pharm Sin (药学学报), 1985, 20: 821-826.
6
Ji XJ, Zhang FR. Studies on antineoplastic action of indirubin derivatives and analogues and their structure activity relationships [J]. Acta Pharm Sin (药学学报), 1985, 20: 137-139.
7
Hoessel R, Leclerc S, Eedicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependant kinases [J]. Nat Cell Biol, 1999, 1: 60-67.
8
Zhang ZX, Li SY, Li FF, et al. Meisoindigo acts as a molecular glue to target PKMYT1 for degradation in chronic myeloid leukemiha therapy [J]. Adv Sci, 2025, 12: e2413676.
9
Steinebach C, Bricelj A, Murgai A, et al. Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs [J]. J Med Chem, 2023, 66: 14513-14543.
10
Liu TT, Yang H, Zhuo FF, et al. Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy [J]. eBioMedicine, 2022, 86: 104353.
2025年第60卷第10期
PDF下载
164
77
引用本文
BibTeX
文章信息
doi: 10.16438/j.0513-4870.2025-0741
  • 接收时间:2025-06-30
  • 首发时间:2026-09-20
  • 出版时间:2025-10-12
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-06-30
  • 修回日期:2025-07-25
基金
作者信息
    中国医学科学院、北京协和医学院药物研究所, 北京 100050

通讯作者:

郭宗儒, E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/yxxb/CN/10.16438/j.0513-4870.2025-0741
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏